A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation
Clinicaltrials.gov identifier:
NCT06005974 (https://clinicaltrials.gov/show/NCT06005974)
Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation
Study Contact Information:
Study Contact: Recursion Pharmaceuticals
By phone: 385-374-1724
By email: [email protected]
Tempus Labs
Study Contact: [email protected]
About the Study
This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation. REC-4881 is a type of targeted therapy drug known as a MEK1/2 inhibitor.
What the Study Involves
Participants will be assigned to one of two groups based on the results of tumor testing. All participants will receive the drug REC-4881.
- Group 1: tumors with AXIN1 mutations
- Group 2: tumors with APC mutations (this may include people with an inherited APC mutation and/or a type of inherited syndrome known as Familial Adenomatous Polyposis (FAP or AFAP)
Participants will take REC-4881 once daily by mouth for up to 2 years. Follow up will include office visits, lab tests and imaging to track response to the treatment.
Study Locations
Note: For all study locations, the contact is: [email protected].
Arizona
- Yuma, AZ
Yuma Regional Medical Center
Arkansas
- Springdale, AR
Highlands Oncology
California
- Cerritos, CA
TOI Clinical Research - Fullerton, CA
Providence Medical Foundation (Fullerton) - Long Beach, CA
MemorialCare - Los Alamitos, CA
Cancer and Blood Research Center - San Diego, CA
Sharp HealthCare - Santa Barbara, CA
Ridley-Tree Cancer Center - Santa Rosa, CA
Providence Medical Foundation (Santa Rosa)
Connecticut
- Norwich, CT
Eastern Connecticut Hematology & Oncology Associates
Florida
- Fort Lauderdale, FL
Holy Cross Hospital - Jacksonville, FL
Cancer Specialists of North Florida - Lakeland, FL
TOI Florida
Georgia
- Athens, GA
University Cancer & Blood Center
Illinois
- Hinsdale, IL
Hope and Healing Cancer Services - Rolling Meadows, IL
Northwest Oncology & Hematology
Indiana
- Fort Wayne, IN
Fort Wayne Medical Oncology and Hematology - Indianapolis, IN
Community Health Network
Louisiana
- Baton Rouge, LA
Our Lady of the Lake
Maryland
- Germantown, MD
The Center for Cancer and Blood Disorders
Massachusetts
- Fairhaven, MA
Southcoast Centers for Cancer Care
Missouri
- Saint Joseph, MO
Mosaic Life Care
Nebraska
- Omaha, NE
Nebraska Cancer Specialists
Nevada
- Las Vegas, NV
OptumCare Cancer Care - Las Vegas, NV
Comprehensive Cancer Centers of Nevada
New Jersey
- Belleville, NJ
New Jersey Cancer Care - Englewood, NJ
Englewood Health - Florham Park, NJ
Summit Medical Group
New York
- East Syracuse, NY
HOACNY
North Dakota
- Fargo, ND
Sanford Health - Fargo
Ohio
- Canton, OH
Aultman Medical Group - Cincinnati, OH
TriHealth Cancer Institute - Toledo, OH
The Toledo Clinic
Oklahoma
- Oklahoma City, OK
Ssm Health Care Of Oklahoma- Inc. - Tulsa, OK
Oklahoma Cancer Specialists and Research Institute
Oregon
- Salem, OR
Oregon Oncology Specialists
Pennsylvania
- Gettysburg, PA
PCSRI - Gettysburg - York, PA
Cancer Care Associates of York
South Carolina
- Greenville, SC
Bon Secours (Greenville) - St. Francis Cancer Center
South Dakota
- Sioux Falls, SD
Sanford Health - Sioux Falls, SD
Avera Cancer Institute
Texas
- Houston, TX
Oncology Consultants - Sugar Land, TX
Lumi Research
Utah
- Salt Lake City, UT
Utah Cancer Specialists
Virginia
- Fredericksburg, VA
Hematology Oncology Associates of Fredericksburg
Washington
- Bellingham, WA
PeaceHealth - Olympia, WA
Vista Oncology - Spokane, WA
Cancer Care Northwest - Tacoma, WA
Northwest Medical Specialties
Wisconsin
- Appleton, WI
ThedaCare - La Crosse, WI
Gundersen Health System
This Study is Open To:
- People with the following may be eligible:
- 55 years of age or older with locally advanced, or metastatic solid tumor with AXIN1 or APC mutation.
- People with an APC mutation with colorectal cancer must not have a RAS / RAF mutation.
- Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic treatment, or are ineligible for standard therapy.
- Have measurable disease.
This Study is Not Open To:
The following people are not eligible:
- People who received treatment with MEK inhibitor drug must wait at least 2 months before the first dose of REC-4881.
- People with heart disease measured by echocardiogram (ECHO) or MUGA scan.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.